Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Safety topic
No spam. Unsubscribe anytime.
Supporters urge in‑person oversight for 'high‑risk' drugs in Patient Protection Act; witnesses cite insurance‑claims analyses on mifepristone
Summary
Proponent witnesses and advocacy groups told the Senate Health Committee House Bill 324 would require in‑person evaluations and strengthened physician oversight for medications with higher than 5% serious adverse‑event rates; sponsors and witnesses repeatedly cited large insurance‑claims analyses for mifepristone and urged patient safeguards, while senators asked for the underlying data and definitions.
Supporters of House Bill 324, the Patient Protection Act, told the Senate Health Committee the bill would require in‑person evaluations and direct medical involvement before dispensing medications that show a serious adverse‑event rate above 5 percent. Witnesses from Ohio Right to Life, the Center for Christian Virtue, and the Catholic Conference of Ohio urged the committee to close what they described as gaps in telehealth prescribing and distribution for certain high‑risk medications, frequently citing recent insurance‑claims analyses of mifepristone and case examples.
A witness described an analysis of more than 860,000 mifepristone prescriptions and said it found an approximately 11 percent rate of serious adverse events within 45 days (sepsis, hemorrhage, transfusion, hospitalization, surgical intervention). Witnesses said the bill would not ban medications but would require a before‑and‑after in‑person visit for drugs on a public list maintained by Ohio health agencies; the sponsors said “high‑risk” is defined in the bill as drugs with higher than a 5 percent serious adverse‑event rate and that the list could be extensive.
Committee members asked for the data sources and methodology behind the cited figures and noted that some referenced analyses are not peer‑reviewed. Several members also asked whether the proposal would block telehealth for other important medications and what constitutes the 5 percent calculation. Witnesses agreed to provide the supporting data and the committee requested the materials. Supporters argued the in‑person layer of oversight is necessary for gestational age verification in abortion care and broader patient safety; opponents and skeptical members raised concerns about substituting insurance‑claims analyses for peer‑reviewed evidence.
No vote was taken on HB 324 at the hearing; witnesses said they would supply additional documentation requested by the committee.
